Form 4: Dianthus Therapeutics Director Alison Frances Lawton Acquires Stock Options

Alison Frances Lawton, a director of Dianthus Therapeutics, acquired 11,000 stock options on May 23, 2024, at an exercise price of $21.77.

Summary

• On May 23, 2024, Alison Frances Lawton, a director of Dianthus Therapeutics, acquired 11,000 stock options.
• The exercise price for these options is $21.77.
• The options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service to the Issuer.
• The options expire on May 22, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Future Outlook

The vesting of the stock options is contingent upon the director's continued service to Dianthus Therapeutics.

Industry Context

This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates